Target Name: MIR3136
NCBI ID: G100422859
Review Report on MIR3136 Target / Biomarker Content of Review Report on MIR3136 Target / Biomarker
MIR3136
Other Name(s): MicroRNA 3136 | hsa-miR-3136-5p | mir-3136 | microRNA 3136 | hsa-miR-3136-3p | hsa-mir-3136

MIR3136: A Potential Drug Target and Biomarker for Obesity

Obesity has become a significant public health issue in recent years, with an estimated 20% of adults worldwide classified as obese or overweight. The consequences of obesity are numerous, including increased risk of cardiovascular disease, diabetes, and certain cancers. MIR3136 is a potential drug target and biomarker that may offer new insights into the treatment and diagnosis of obesity.

MIR3136 is a microRNA (miRNA) that has been shown to play a critical role in the regulation of energy metabolism and body weight. It is a non-coding RNA molecule that contains 20 amino acid residues and is expressed in various tissues and organs, including adipose tissue, muscle, and liver. MIR3136 has been shown to regulate the expression of genes involved in energy metabolism, such as those involved in lipid metabolism, and has been linked to the development of obesity.

In addition to its role in energy metabolism, MIR3136 has also been shown to play a key role in the regulation of cellular processes that are associated with obesity, such as inflammation and fibrosis. MIR3136 has been shown to promote the production of pro-inflammatory cytokines, such as TNF-伪, and to inhibit the production of anti-inflammatory cytokines, such as IL-10. These processes may contribute to the development of obesity and the associated health problems.

MIR3136 has also been shown to be involved in the regulation of cellular processes that are involved in the development of type 2 diabetes. MIR3136 has been shown to promote the production of GLUT-1, a protein that is involved in glucose uptake and storage in muscle fibers, and has been linked to the development of insulin resistance and type 2 diabetes.

In addition to its potential role in the development of obesity and type 2 diabetes, MIR3136 has also been shown to have potential therapeutic applications. For example, studies have shown that MIR3136 can be used to target and reduce the expression of genes involved in energy metabolism, such as those involved in lipid metabolism. This may result in a reduction in body weight and improved energy metabolism.

Another potential application of MIR3136 is its potential as a biomarker for the diagnosis and monitoring of obesity. Obesity can be a difficult condition to diagnose, as it often does not present with any noticeable physical symptoms. In addition, the development of obesity can be a slow and gradual process, making it difficult to monitor the effectiveness of treatments. MIR3136 may offer a new way to diagnose and monitor obesity by providing a reliable and sensitive biomarker for obesity.

MIR3136 has been shown to be involved in the regulation of various biological processes that are associated with obesity, including energy metabolism, inflammation, and fibrosis. Its potential as a drug target and biomarker for obesity makes it an attractive target for further research and development.

In conclusion, MIR3136 is a potential drug target and biomarker for obesity. Its role in energy metabolism, inflammation, and fibrosis, as well as its potential therapeutic applications, make it an attractive target for further research and development. Further studies are needed to fully understand the potential of MIR3136 as a drug target and biomarker for obesity.

Protein Name: MicroRNA 3136

The "MIR3136 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR3136 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR3137 | MIR3138 | MIR3139 | MIR3140 | MIR3141 | MIR3142 | MIR3142HG | MIR3143 | MIR3144 | MIR3145 | MIR3146 | MIR3147 | MIR3147HG | MIR3148 | MIR3149 | MIR3150A | MIR3150B | MIR3151 | MIR3152 | MIR3153 | MIR3154 | MIR3155A | MIR3155B | MIR3156-1 | MIR3156-2 | MIR3156-3 | MIR3157 | MIR3158-1 | MIR3158-2 | MIR3159 | MIR3160-1 | MIR3160-2 | MIR3161 | MIR3162 | MIR3163 | MIR3164 | MIR3165 | MIR3166 | MIR3167 | MIR3168 | MIR3169 | MIR3170 | MIR3171 | MIR3171HG | MIR3173 | MIR3174 | MIR3175 | MIR3176 | MIR3177 | MIR3178 | MIR3179-1 | MIR3179-2 | MIR3179-3 | MIR3180-1 | MIR3180-2 | MIR3180-3 | MIR3180-4 | MIR3180-5 | MIR3182 | MIR3183 | MIR3184 | MIR3185 | MIR3186 | MIR3187 | MIR3188 | MIR3189 | MIR3190 | MIR3191 | MIR3192 | MIR3193 | MIR3194 | MIR3195 | MIR3196 | MIR3197 | MIR3198-1 | MIR3199-1 | MIR3199-2 | MIR31HG | MIR32 | MIR3200 | MIR3201 | MIR3202-1 | MIR3202-2 | MIR320A | MIR320B1 | MIR320B2 | MIR320C1 | MIR320C2 | MIR320D1 | MIR320D2 | MIR320E | MIR323A | MIR323B | MIR324 | MIR325 | MIR325HG | MIR326 | MIR328 | MIR329-1 | MIR329-2